{"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"22"},{"groupId":"BG003","value":"36"},{"groupId":"BG004","value":"37"},{"groupId":"BG005","value":"101"}],"units":"Participants"}],"groups":[{"description":"Elotuzumab 5 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"BG000","title":"Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone (Phase 1)"},{"description":"Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"BG001","title":"Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 1)"},{"description":"Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"BG002","title":"Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 1)"},{"description":"Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"BG003","title":"Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 2)"},{"description":"Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"BG004","title":"Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 2)"},{"description":"Total of all reporting groups","id":"BG005","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"7.23","value":"68.3"},{"groupId":"BG001","spread":"6.94","value":"64.7"},{"groupId":"BG002","spread":"10.87","value":"59.3"},{"groupId":"BG003","spread":"9.70","value":"60.6"},{"groupId":"BG004","spread":"9.76","value":"63.3"},{"groupId":"BG005","spread":"9.91","value":"61.7"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"19"},{"groupId":"BG004","value":"24"},{"groupId":"BG005","value":"56"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"17"},{"groupId":"BG004","value":"13"},{"groupId":"BG005","value":"45"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Safety population: all randomized participants who received at least 1 dose of study drug"}